Jubilant Ingrevia Q4 FY26: Revenue Up 12% to ₹1,179 Cr, EBITDA Rises 11% to ₹172 Cr
Jubilant Ingrevia reported Q4 FY26 revenue of ₹1,179 crore (up 12% YoY) and EBITDA of ₹172 crore (up 11% YoY). The company recommended a final dividend of ₹2.50 per share. Key highlights include the acquisition of Remidex Pharma and effective management of supply chain disruptions. FY27 outlook is positive, expecting growth led by Specialty Chemicals and Nutrition.
The announcement details significant financial growth, a recommended dividend payout, and strategic acquisitions, all of which are material events for investors and indicate strong business performance and future prospects.
The company reported strong year-on-year growth in revenue and EBITDA, highlighted positive business segment performance, and expressed confidence in future growth, supported by strategic acquisitions and effective operational management.
Jubilant Ingrevia Limited announced strong financial results for the fourth quarter and full financial year ended March 31, 2026. The company reported a total revenue of ₹1,179 crore for Q4 FY26, marking a 12% year-on-year increase, and EBITDA of ₹172 crore, up 11% year-on-year. This performance reflects strong execution and effective handling of global challenges, including the Middle East crisis, which resulted in no force majeure or production loss.
The company's Speciality Chemicals segment saw revenue grow by 6% year-on-year to ₹516 crore, with EBITDA at ₹139 crore and margins around 27%. Key drivers included strong volume momentum in Pyridine & derivatives and commencement of dispatches from the new Agro CDMO facility. The Nutrition & Health Solutions segment reported a revenue increase of 21% year-on-year to ₹230 crore, with EBITDA at ₹32 crore. Growth was led by Niacinamide and the acquisition of Remidex Pharma, which is expected to accelerate the Human Nutrition business.
The Chemical Intermediates segment revenue grew by 15% year-on-year to ₹433 crore. The company highlighted improved EBITDA supported by cost pass-through and increased domestic volumes in agrochemical and paracetamol demand. Overall for FY26, revenue stood at ₹4,388 crore, a 5% increase from FY25, and EBITDA was ₹607 crore, up 9% year-on-year.
Management expressed confidence in sustained growth across segments for FY27, expecting growth to be led by Specialty Chemicals and Nutrition, with a recovery in Acetyls. The company also recommended a final dividend of ₹2.50 per share (250%), bringing the total dividend for FY26 to ₹5 per share (500%). Future investments include the ongoing construction of the Gajraula Multi Purpose Plant (MPP).
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.